Literature DB >> 12850245

Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors.

Akiko Kojima-Yuasa1, Jin Jin Hua, David Opare Kennedy, Isao Matsui-Yuasa.   

Abstract

Epidemiological and animal studies have indicated that consumption of green tea is associated with a reduced risk of developing certain forms of cancer. However, the inhibitory mechanism of green tea in angiogenesis, an important process in tumor growth, has not been well established. In the present study, green tea extract (GTE) was tested for its ability to inhibit cell viability, cell proliferation, cell cycle dynamics, vascular endothelial growth factor (VEGF) and expression of VEGF receptors fms-like tyrosine kinase (Flt-1) and fetal liver kinase-1/Kinase insert domain containing receptor (Flk-1/KDR) in vitro using human umbilical vein endothelial cells (HUVECs). GTE in culture media did not affect cell viability but significantly reduced cell proliferation dose-dependently and caused a dose-dependent accumulation of cells in the G1 phase. The decrease of the expression of Flt-1 and KDR/Flk-1 in HUVEC by GTE was detected with immunohistochemical and Western blotting methods. These results suggest that GTE may have preventive effects on tumor angiogenesis and metastasis through reduction of expression of VEGF receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12850245     DOI: 10.1016/s0024-3205(03)00424-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  19 in total

Review 1.  Phenylpropanoids in radioregulation: double edged sword.

Authors:  Wanyeon Kim; Ki Moon Seong; BuHyun Youn
Journal:  Exp Mol Med       Date:  2011-06-30       Impact factor: 8.718

Review 2.  Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis.

Authors:  Manoj Kumar; Sunil Kumar Dhatwalia; D K Dhawan
Journal:  Tumour Biol       Date:  2016-09-10

3.  A survey on herbal management of hepatocellular carcinoma.

Authors:  Nabil Mohie Abdel-Hamid; Maiiada Hasan Nazmy; Ahmed Wahid Mahmoud; Michael Atef Fawzy; Marco Youssof
Journal:  World J Hepatol       Date:  2011-07-27

Review 4.  Perspectives on the recent developments with green tea polyphenols in drug discovery.

Authors:  Feng Li; Yongli Wang; Dapeng Li; Yilun Chen; Xuguang Qiao; Rania Fardous; Ashton Lewandowski; Jinbao Liu; Tak-Hang Chan; Q Ping Dou
Journal:  Expert Opin Drug Discov       Date:  2018-04-24       Impact factor: 6.098

5.  Combined low dose ionizing radiation and green tea-derived epigallocatechin-3-gallate treatment induces human brain endothelial cells death.

Authors:  Nancy McLaughlin; Borhane Annabi; Marie-Paule Lachambre; Kwang Sik Kim; Jean-Paul Bahary; Robert Moumdjian; Richard Béliveau
Journal:  J Neurooncol       Date:  2006-05-19       Impact factor: 4.130

6.  Therapeutic efficacy of topical epigallocatechin gallate in murine dry eye.

Authors:  Hyun Soo Lee; Sunil K Chauhan; Andre Okanobo; Nambi Nallasamy; Reza Dana
Journal:  Cornea       Date:  2011-12       Impact factor: 2.651

Review 7.  Green tea polyphenols as proteasome inhibitors: implication in chemoprevention.

Authors:  H Yang; K Landis-Piwowar; T H Chan; Q P Dou
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

Review 8.  Cancer and metastasis: prevention and treatment by green tea.

Authors:  Naghma Khan; Hasan Mukhtar
Journal:  Cancer Metastasis Rev       Date:  2010-09       Impact factor: 9.264

9.  Green tea catechins inhibit angiogenesis through suppression of STAT3 activation.

Authors:  Hoyee Leong; Priya S Mathur; Geoffrey L Greene
Journal:  Breast Cancer Res Treat       Date:  2008-09-28       Impact factor: 4.872

10.  (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis.

Authors:  Bao-He Zhu; Wen-Hua Zhan; Zheng-Rong Li; Zhao Wang; Yu-Long He; Jun-Sheng Peng; Shi-Rong Cai; Jin-Ping Ma; Chang-Hua Zhang
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.